^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BCR-ABL1 H396R

i
Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
6ms
A New Next-generation sequencing based assay for BCR-ABL1 kinase domain mutation detection in patients with chronic myeloid leukemia (AMP 2023)
In summary, our newly developed assay can be used for kinase domain mutation analysis from clinical samples and with very good sensitivity of 2%, which is in a well-acceptable range of 1% to 3% and is available on commonly used the Ion Torrent platform. This ability of the assay in detecting low-level variants and even compound variants makes it very important for selection of appropriate TKIs for CML patients.
Clinical • Next-generation sequencing
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
BCR-ABL1 F317L • BCR-ABL1 Y253H • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 H396R • BCR-ABL1 Y253F • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 E459K • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 Y253H
over3years
Clinical • New trial
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T
|
dasatinib • imatinib • Tasigna (nilotinib) • Hansoh Xinfu (flumatinib)